Tiflorex
- none
- (RS)-N-ethyl-1-{3-[(trifluoromethyl)thio]phenyl}propan-2-amine
- 53993-67-2 Y
- 173669
- 151574 N
- EG3B69DFQ5
- DTXSID90866374
- Interactive image
- CCNC(C)Cc1cccc(c1)SC(F)(F)F
- InChI=1S/C12H16F3NS/c1-3-16-9(2)7-10-5-4-6-11(8-10)17-12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3 N
- Key:HNONSDNCRNUTCT-UHFFFAOYSA-N N
Tiflorex (TFX), formerly known as flutiorex, is a stimulant[citation needed] amphetamine that was under development as an appetite suppressant in the 1970s,[1][2] but appears to have been abandoned. It is structurally related to fenfluramine and 4-MTA.
Tiflorex went to phase II clinical trials. The extended release formulation "TFX-SR" produced significant suppression of appetite. It also caused slightly more sleep disturbances and headaches than placebo, as well as mydriasis and a self-reported decrease in arousal. It had little effect on heart rate.[2]
Tifluorex is claimed to be a more potent anorectic than fenfluramine, with twice its potency in humans[2] and 4 times its potency in rats.[3]
Pharmacology
Pharmacodynamics
The mechanism of action of tiflorex has apparently never been studied. Similar compounds such as fenfluramine, norfenfluramine and 4-MTA act as selective serotonin releasing agents and 5-HT2 receptor agonists. Fenfluramine in particular causes very similar side effects and appetite suppression at therapeutically relevant doses.
Pharmacokinetics
In rats, tiflorex is rapidly N-dealkylated to norflutiorex. Both tiflorex and norflutiorex appear to be excreted in urine.[1]
Synthesis
The Rosenmund reduction of 3-(trifluoromethylthio)benzoyl chloride [51748-28-8] (1) gave 3-((trifluoromethyl)thio)benzaldehyde [51748-27-7] (2). Henry reaction with nitroethane led to 1-(2-nitroprop-1-en-1-yl)-3-[(trifluoromethyl)sulfanyl]benzene [176242-84-5] (3). With the aid of iron catalyst in concentrated HCl acid there occurred FGI into 1-(3'-trifluoromethylthiophenyl)-2-propanone, CID:21325269 (4'). Reductive amination with ethylamine and formic acid as the reductant completed the synthesis of tiflorex (5).
References
- ^ a b Giudicelli JF, Richer C, Berdeaux A (February 1976). "Preliminary assessment of flutiorex, a new anorectic drug, in man". British Journal of Clinical Pharmacology. 3 (1): 113–21. doi:10.1111/j.1365-2125.1976.tb00578.x. PMC 1428817. PMID 788737.
- ^ a b c Silverstone T, Fincham J, Plumley J (April 1979). "An evaluation of the anorectic activity in man of a sustained release formulation of tiflorex". British Journal of Clinical Pharmacology. 7 (4): 353–6. doi:10.1111/j.1365-2125.1979.tb00945.x. PMC 1429648. PMID 444355.
- ^ Stuart S (2013-09-11). Abstracts: Sixth International Congress of Pharmacology. Elsevier. ISBN 9781483152530.
- ^ Don P. R. L. Giudicelli & Henry Najer, U.S. patent 4,148,923 (1979 to Synthelabo SA).
- v
- t
- e
antagonists
glucagon agonists
receptor agonists
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e